Citations

Clear

76 citation(s) found for "Gore, Steven".

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
Garcia‐Manero, Guillermo , Gore, Steven D. , Scott, Bart L. , Tefferi, Ayalew , Edenfield, William J. , Hetzer, Joel, Kumar, Keshava, Skikne, Barry, Kambhampati, Suman , Cogle, Christopher Ramin

Mayo Clinic

Blood | October 9, 2019 | Volume: 120 | Issue: 21 | Pages: 424-424

10.1182/blood.v120.21.424.424 Get It

Abstract Abstract 424 Background: Azacitidine for injection has been shown to prolong overall survival in patients (pts) with higher-risk myelodysplastic syndromes (MDS) compared with conventional care regimens (CCR) (Lancet Oncol, 2009). An oral formulation of azacitidine (CC-486) is in development. Oral azacitidine may maximize convenience, eliminate injection-site reactions, and if administered in extended dosing schedules, may enhance and prolong the therapeutic effects of azacitidine. Oral azacitidine administered once-daily (QD) for 7 days (d) of repeated 28d cycles has been shown to be bioavailable, biologically and clinically active, and well-tolerated in pts with MDS and acute myeloid leukemia (Garcia-Manero, J Clin Oncol, 2011). Preliminary evidence suggests that extending oral azacitidine dosing to 14d or 21d of the 28d cycle may enhance pharmacodynamic and epigenetic activity (Laille, Leuk Res, 2011). Purpose: To evaluate hematologic response and safety associated with extended dosing regimens of oral azacitidine in pts with lower-risk MDS. Methods: This ongoing, multicenter, phase 1 study, enrolled pts with lower-risk (IPSS Low or INT-1) MDS who were RBC transfusion dependent (TD) and/or thrombocytopenic (average platelet count ≤50,000 within 56d prior to the first dose) at baseline. Pts were sequentially assigned to receive oral azacitidine 300mg QD for either 14d or 21d of repeated 28d cycles. Hematologic assessments were made every 2 weeks. Hematologic response was assessed using IWG 2006 criteria (Cheson, Blood, 2006). Adverse events (AEs) were graded using NCI-CTCAE version 3.0. Results: At data cut-off (May 18, 2012), 53 pts with lower-risk MDS had enrolled (300mg oral azacitidine QDx14d, n=26; QDx21d, n=27). Demographic and disease characteristics at baseline were similar in the 14d and 21d treatment cohorts (Table 1). Median (range) hematology counts at baseline were Hgb 8.7 g/L (6.0–13.0), ANC 1.6×109/L (0–30.3), and platelets 56.0×109/L (6.0–564.0). At study entry, 40% of pts had received no prior MDS treatment (except transfusions), 45% had received erythropoiesis-stimulating agents, and 15% had received WBC growth factors. The number of oral azacitidine treatment cycles received ranged from 1 to 12 (median numbers of oral azacitidine cycles were 6 in the QDx14d and 4 in the QDx21d cohorts). Four pts in the 21d cohort and 1 pt in the 14d cohort received reduced oral azacitidine doses (200mg QD). Overall, 10 pts discontinued the study, including 6 pts (3 pts in each cohort) who discontinued due to AEs that may have been treatment-related (gastrointestinal [n=2] or intracranial [n=1] hemorrhage, febrile neutropenia [n=1], pneumonia [n=1], thrombocytopenia [n=1]). Overall response rates (ORR), which included complete (CR) and partial remission (PR), any hematologic improvement (HI), and transfusion independence (TI), ranged from 38.5% in the QDx14d cohort to 29.6% in the QDx21d cohort, and RBC TI was achieved by 47% and 33%, respectively, of pts who were RBC TD at baseline (Table 2). For pts who received at least 4 cycles of oral azacitidine (14d, n=19; 21d, n=14), ORR was 47.4% in the 14d and 50.0% in the 21d cohorts, and RBC TI rates in RBC TD pts (n=16) were 67% in the 14d and 57% in the 21d cohorts. The most frequent (≥5%) grade 3/4 hematologic AEs in the QDx14d cohort were anemia (11.5%), thrombocytopenia (11.5%), and neutropenia (7.7%); and in the QDx21d cohort were neutropenia (14.8%), anemia (7.4%), and febrile neutropenia (7.4%). Most frequent grade 3/4 non-hematologic AEs were gastrointestinal, including vomiting (7.7%) in the QDx14d cohort, and diarrhea (11.1%) and vomiting (7.4%) in the QDx21d cohort. Conclusions: Oral azacitidine 300mg QD administered in extended dosing schedules of 14d or 21d of repeated 28d cycles was effective and well-tolerated in these pts with lower-risk MDS. Beside hematologic AEs, the most frequently observed AEs with oral azacitidine were gastrointestinal and were manageable. Efficacy and safety outcomes with 300mg QD oral azacitidine were generally comparable between the 14d and 21d extended dosing regimens. Based on these data, oral azacitidine administered once-daily in extended dosing schedules is active and well-tolerated and warrants further investigation in randomized, controlled trials. Disclosures: Garcia-Manero: Celgene: Research Funding, Speakers Bureau. Gore:Celgene Corporation: Consultancy, Research Funding. Scott:Celgene Corporation: Honoraria, Research Funding, Speakers Bureau. Hetzer:Celgene Corporation: Employment, Equity Ownership. Kumar:Celgene Corporation: Employment, Equity Ownership. Skikne:Celgene: Employment, Equity Ownership.
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Stahl, Maximilian , DeVeaux, Michelle, Montesinos, Pau , Itzykson, Raphaël , Ritchie, Ellen K. , Sekeres, Mikkael A. , Brunner, Andrew M. , Komrokji, Rami S. , Bhatt, Vijaya Raj , Al‐Kali, Aref , Cluzeau, Thomas , Santini, Valeria , Fathi, Amir T. , Fenaux, Pierre , Litzow, Mark R. , Kim, Tae Kon , Vey, Norbert , Germing, Ulrich, Bergua, Juan , Gore, Steven D. , Zeidan, Amer M. , Komrokji, Rami S , Bergua, Juan Miguel , Sekeres, Mikkael A , Montesinos, Pau , Bhatt, Vijaya Raj , Itzykson, Raphael , Santini, Valeria , Kim, Tae Kon , Barnard, John , Podoltsev, Nikolai , Roboz, Gail J. , Perreault, Sarah , Prébet, Thomas , Verma, Vivek , Germing, Ulrich , Serrano, Josefina , Zeidan, Amer M

Mayo Clinic

Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 923-932

10.1182/bloodadvances.2018016121 | PMID 29685952 Get It

Key Points In the largest study of HMAs in RR-AML to date, 16% of patients achieved CR/CRi and experienced a median OS of 21 months. Low proliferative disease (peripheral blood blasts <5%) was associated with improved response and OS.
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey
Stahl, Maximilian , Pine, Alexander B. , Litzow, Mark R. , Luger, Selina M. , Stone, Richard M. , Kim, Tae Kon , Sekeres, Mikkael A. , Komrokji, Rami S. , Gore, Steven D. , Zeidan, Amer M. , Litzow, Mark R. , Komrokji, Rami S , Sekeres, Mikkael A , Kim, Tae Kon , Hendrickson, Jeanne E. , Erba, Harry Paul , Steensma, David P. , Zeidan, Amer M

Mayo Clinic

Leukemia & Lymphoma | April 18, 2018 | Volume: 59 | Issue: 11 | Pages: 2723-2726

10.1080/10428194.2018.1452219 | PMID 29667455 Get It

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States
Pine, Alexander B. , Sekeres, Mikkael A. , Zelterman, Daniel , Komrokji, Rami S. , Litzow, Mark R. , Luger, Selina M. , Stone, Richard M. , Garcia‐Manero, Guillermo , Lee, Alfred Ian , Barbarotta, Lisa, Kasberg, Stephanie, Gore, Steven D. , Zeidan, Amer M. , Lee, Eun‐Ju , Steensma, David P. , Prébet, Thomas , Dezern, Amy Elizabeth , Erba, Harry Paul , Podoltsev, Nikolai , Hendrickson, Jeanne E. , Komrokji, Rami S , Sekeres, Mikkael A , Zeidan, Amer M

Mayo Clinic

Transfusion | November 23, 2016 | Volume: 57 | Issue: 2 | Pages: 289-295

10.1111/trf.13934 | PMID 27878822 Get It

BACKGROUNDTransfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high‐quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients.STUDY DESIGN AND METHODSA 31‐question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures.RESULTSWe analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures.CONCLUSIONSThis survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence‐based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Pratz, Keith W. , Gojo, Ivana , Litzow, Mark R. , McDevitt, Michael A. , Ji, Jiuping , Karnitz, Larry M., Herman, James G. , Kinders, Robert J. , Gore, Steven D. , Showel, Margaret M. , Gladstone, Douglas E. , Tsai, Hua-Ling, Rosner, Gary L. , Chen, Alice P. , Karp, Judith E. , Kaufmann, Scott H. , Rudek, Michelle A. , Smith, B. Douglas , Carraway, Hetty E. , Levis, Mark J. , Tsai, Hua‐Ling

Mayo Clinic

Clinical Cancer Research | August 22, 2016 | Volume: 23 | Issue: 4 | Pages: 899-907

10.1158/1078-0432.ccr-16-1274 | PMID 27551000 Get It

Abstract Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10–100 mg orally twice daily on days 1–8, 1–14, or 1–21 along with continuous infusion topotecan 1.0–1.2 mg/m2/d + carboplatin 120–150 mg/m2/d on days 3–7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage–induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95% confidence interval, 0.27–0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias. Clin Cancer Res; 23(4); 899–907. ©2016 AACR.
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Gojo, Ivana , Pratz, Keith W. , McDevitt, Michael A. , Baer, Maria R. , Gore, Steven D. , Showel, Margaret M. , Gladstone, Douglas E. , Ji, Jiuping Jay, Wang, Lihua , Kinders, Robert J. , Pouquet, Marie , Walbi, Ismail A. , Poh, Weijie , Herman, James G. , Karnitz, Larry M., Chen, Alice P. , Karp, Judith E. , Kaufmann, Scott H. , Beumer, Jan Hendrik , Blackford, Amanda , Smith, B. Douglas , Carraway, Hetty E. , Levis, Mark J. , Dezern, Amy Elizabeth , Ji, Jiuping , Rudek, Michelle A. , Poh, Weijie

Mayo Clinic

Clinical Cancer Research | August 8, 2016 | Volume: 23 | Issue: 3 | Pages: 697-706

10.1158/1078-0432.ccr-16-0984 | PMID 27503200 Get It

Abstract Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patients with relapsed, refractory acute myeloid leukemia (AML) or AML arising from aggressive myeloid malignancies. Experimental Design: Patients received veliparib [20–200 mg once a day on day 1 and twice daily on days 4–12 in cycle 1 (days 1–8 in cycle ≥2)] and temozolomide [150–200 mg/m2 daily on days 3–9 in cycle 1 (days 1–5 in cycle ≥2)] every 28 to 56 days. Veliparib pharmacokinetics and pharmacodynamics [ability to inhibit poly(ADP-ribose) polymer (PAR) formation and induce H2AX phosphorylation] were assessed. Pretreatment levels of MGMT and PARP1 protein, methylation of the MGMT promoter, and integrity of the Fanconi anemia pathway were also examined. Results: Forty-eight patients were treated at seven dose levels. Dose-limiting toxicities were oral mucositis and esophagitis lasting &gt;7 days. The MTD was veliparib 150 mg twice daily with temozolomide 200 mg/m2 daily. The complete response (CR) rate was 17% (8/48 patients). Veliparib exposure as well as inhibition of PAR polymer formation increased dose proportionately. A veliparib-induced increase in H2AX phosphorylation in CD34+ cells was observed in responders. Three of 4 patients with MGMT promoter methylation achieved CR. Conclusions: Veliparib plus temozolomide is well tolerated, with activity in advanced AML. Further evaluation of this regimen and of treatment-induced phosphorylation of H2AX and MGMT methylation as potential response predictors appears warranted. Clin Cancer Res; 23(3); 697–706. ©2016 AACR.
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Prébet, Thomas , Sun, Zhuoxin , Ketterling, Rhett P. , Zeidan, Amer M. , Greenberg, Peter L. , Herman, James G. , Malick, Lisa, Paietta, Elisabeth , Czader, Magdalena , Figueroa, María E. , Gabrilove, Janice , Tallman, Martin S. , Litzow, Mark R. , Gore, Steven D. , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Juckett, Mark , Smith, Mitchell R. , Erba, Harry Paul , intergroup, the Eastern Cooperative Oncology Group and North American Leukemia, Prebet, Thomas , Ketterling, Rhett P , Zeidan, Amer M

Mayo Clinic

British Journal of Haematology | November 18, 2015 | Volume: 172 | Issue: 3 | Pages: 384-391

10.1111/bjh.13832 | PMID 26577691 Get It

AbstractTherapy‐related myeloid neoplasms (tMN) are serious late effects of the treatment of cancer with poor response to conventional treatment. Azacitidine (AZA) has been used to treat patients with tMN but current data are retrospective. We present here 47 tMN patients prospectively enrolled as a specific cohort in the E1905 study. TheE1905 study was a randomized phase 2 study (NCT00313586) testing 10 d of AZA (50 mg/m2/d) +/− the histone deacetylase inhibitor entinostat (4 mg/m2/d PO day‐3 and day‐10). A total of 47 patients [29 therapy‐related myelosyspastic syndrome (t‐MDS) and 18 therapy‐related acute myeloid leukaemia (t‐AML)] were recruited to the study. 24 patients were treated with AZA monotherapy and 23 with AZA+entinostat. The median number of administered cycles was 4, significantly higher in patients treated with AZA (6 cycles vs. 3 cycles, P = 0·008). Haematological normalization rates were 46% in monotherapy and 17% in the combination arm. Median overall survivals were 13 and 6 months, respectively. The novel 50 * 10 schedule of azacitidine appears effective, with response rates, when given as single agent, comparable to those for patients with de novo MDS/AML treated on the same protocol. However, the combination of AZA and entinostat was associated with increased toxicity and could not be recommended for treatment of tMN.
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
Correia, Cristina , Schneider, Paula A., Dai, Haiming , Church, Amy K., Novak, Anne J. , Feldman, Andrew L. , Wu, Xiaosheng , Ding, Husheng, Meng, X. Wei, Macon, William R. , Karp, Judith E. , Gore, Steven D. , Jelinek, Diane F., Nowakowski, Grzegorz S. , Doǧan, Ahmet , Maurer, Matthew J. , Cerhan, James R. , Slager, Susan L. , Habermann, Thomas M. , Kay, Neil E. , Witzig, Thomas E. , Kaufmann, Scott H. , Feldman, Andrew L , Correia, Cristina , Dai, Haiming

Mayo Clinic

Blood | December 1, 2014 | Volume: 125 | Issue: 4 | Pages: 658-667

10.1182/blood-2014-04-571786 | PMID 25452615 Get It

Key Points BCL2 mutations in FL correlate with activation-induced cytidine deaminase expression and frequently alter the amino acid sequence of the protein. Mutations in the BCL2 coding sequence at diagnosis are associated with shortened time to transformation and earlier death due to lymphoma.